Encouraging results
The growing incidence of inflammatory bowel disease is cause for concern because it predisposes to colorectal cancer. However, Dr. Jantchou's research team has shown a decline in the relapse rate of Crohn's disease in children in recent years. A sample of 639 patients under the age of 18 diagnosed with Crohn's disease were followed at CHU Sainte-Justine between 2009 and 2019. Of patients diagnosed between 2009 and 2014, 70.9% experienced a resurgence of their disease despite treatment, as compared to 49.1% of patients diagnosed between 2015 and 2019.
This decrease could be due specifically to the increased use of biotherapies in the treatment of inflammatory bowel diseases. This class of drugs targets specific proteins in the inflammatory cascade and includes biologics, made from living cells, and biosimilars, comparable alternatives that are less expensive than biologics.
“More important is that children can be kept in remission with biologic treatments formulated to target inflammatory molecules. In fact, 50% of patients newly diagnosed with this disease will receive a biologic treatment within three months of follow-up, thus allowing control of the disease before they develop severe symptoms,” states Dr. Prévost Jantchou.